Journal of Medicinal Chemistry
Article
⊥Department of Chemistry, University of Southern California,
Los Angeles, CA 90089, United States.
Author Contributions
S.L., C.Z., and M.L. contributed equally. The manuscript was
written through contributions of all authors. All authors have
given approval to the final version of the manuscript.
(13) Wernimont, A. K.; Artz, J. D.; Finerty, P.; Lin, Y.; Amani, M.;
Allali-Hassani, A.; S, G.; Vedadi, M.; Tempel, W.; MacKenzie, F.;
Chau, I.; Lourido, S.; Sibley, L. D.; Hui, R. Structures of apicomplexan
calcium-dependent protein kinases reveal mechanism of activation by
calcium. Nature Struct. Mol. Biol. 2010, 17, 596−601.
(14) Bishop, A. C.; Shokat, K. M. Acquisition of inhibitor-sensitive
protein kinases through protein design. Pharmacol. Ther. 1999, 82,
337−346.
Notes
(15) Bishop, A. C.; Ubersax, J. A.; Petsch, D. T.; Matheos, D. P.;
Gray, N. S.; Blethrow, J.; Shimizu, E.; Tsien, J. Z.; Schultz, P. G.; Rose,
M. D.; Wood, J. L.; Morgan, D. O.; Shokat, K. M. A chemical switch
for inhibitor-sensitive alleles of any protein kinase. Nature 2000, 407,
395−401.
(16) Liu, Y.; Bishop, A.; Witucki, L.; Kraybill, B.; Shimizu, E.; Tsien,
J.; Ubersax, J.; Blethrow, J.; Morgan, D. O.; Shokat, K. M. Structural
basis for selective inhibition of Src family kinases by PP1. Chem. Biol.
1999, 6, 671−678.
(17) Liu, Y.; Shah, K.; Yang, F.; Witucki, L.; Shokat, K. M. A
molecular gate which controls unnatural ATP analogue recognition by
the tyrosine kinase v-Src. Bioorg. Med. Chem. 1998, 6, 1219−1226.
(18) Sugi, T.; Kato, K.; Kobayashi, K.; Watanabe, S.; Kurokawa, H.;
Gong, H.; Pandey, K.; Takemae, H.; Akashi, H. Use of the kinase
inhibitor analog 1-NM-PP1 reveals a role for Toxoplasma gondii
CDPK1 in the invasion step. Eukaryotic Cell 2010, 15, 1716−1725.
(19) Wernimont, A. K.; Amani, M.; Qiu, W.; Pizarro, J. C.; Artz, J. D.;
Lin, Y. H.; Lew, J.; Hutchinson, A.; Hui, R. Structures of parasitic
CDPK domains point to a common mechanism of activation. Proteins
2011, 79, 803−820.
(20) Johnson, S. M.; Murphy, R. C.; Geiger, J. A.; DeRocher, A. E.;
Zhang, Z.; Ojo, K. K.; Larson, E. T.; Perera, B. G.; Dale, E. J.; He, P.;
Reid, M. C.; Fox, A. M.; Mueller, N. R.; Merritt, E. A.; Fan, E.;
Parsons, M.; Van Voorhis, W. C.; Maly, D. J. Development of
Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1)
inhibitors with potent anti-toxoplasma activity. J. Med. Chem. 2012, 55,
2416−2426.
(21) Larson, E. T.; Ojo, K. K.; Murphy, R. C.; Johnson, S. M.; Zhang,
Z.; Kim, J. E.; Leibly, D. J.; Fox, A. M.; Reid, M. C.; Dale, E. J.; Perera,
B. G.; Kim, J.; Hewitt, S. N.; Hol, W. G.; Verlinde, C. L.; Fan, E.; Van
Voorhis, W. C.; Maly, D. J.; Merritt, E. A. Multiple determinants for
selective inhibition of apicomplexan calcium-dependent protein kinase
CDPK1. J. Med. Chem. 2012, 55, 2803−2810.
(22) Murphy, R. C.; Ojo, K. K.; Larson, E. T.; Castellanos-Gonzalez,
A.; Perera, B. G.; Keyloun, K. R.; Kim, J. E.; Bhandari, J. G.; Muller, N.
R.; Verlinde, C. L.; White, A. C.; Merritt, E. A.; Van Voorhis, W. C.;
Maly, D. J. Discovery of Potent and Selective Inhibitors of Calcium-
Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.
ACS Med. Chem. Lett. 2010, 1, 331−335.
(23) Salomon, D.; Bonshtien, A.; Mayrose, M.; Zhang, C.; Shokat, K.
M.; Sessa, G. Bypassing kinase activity of the tomato Pto resistance
protein with small molecule ligands. J. Biol. Chem. 2009, 284, 15289−
15298.
(24) Shah, P.; Westwell, A. D. The role of fluorine in medicinal
chemistry. J. Enzyme Inhib. Med. Chem. 2007, 22, 527−540.
(25) Smith, D. A. Discovery and ADMET: Where are we now? Curr.
Top. Med. Chem. 2011, 11, 467−481.
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We are grateful for helpful comments and advice from Ray Hui,
Meg Phillips, and Ildiko Dunay. Partially supported by the
National Institutes of Health grant AI034036. S.L. was partially
supported by a predoctoral fellowship from the American Heart
Association. M.S.L. was supported by a National Science
Foundation Graduate Research Fellowship award.
ABBREVIATIONS USED
■
Atc, anhydrotetracycline; 3-BrB-PP, 3-bromo-benzyl pyrazolo
[3,4-d] pyrimidine; 3-ClB-PP, 3-chloro-benzyl pyrazolo [3,4-d]
pyrimidine; CDPK1, calcium-dependent protein kinase 1; EC50,
half-maximum effective concentration, IC50, half-maximum
inhibitory concentration; 3-MB-PP, 3-methyl-benzyl pyrazolo
[3,4-d] pyrimidine; PP, pyrazolo [3,4-d] pyrimidine
REFERENCES
■
(1) Dubey, J. P., Toxoplasmosis of Animals and Humans; CRC Press:
Boca Raton, 2010; p 313.
(2) Sibley, L. D. Invasion and intracellular survival by protozoan
parasites. Immunol. Rev. 2011, 240, 72−91.
(3) Weiss, L. M.; Kim, K., Bradyzoite development. In Toxoplasma
gondii The Model Apicomplexan: Perspectives and Methods; Weiss, L. M.,
Kim, K., Eds.; Academic Press: New York, 2007; pp 341−366.
(4) Joynson, D. H.; Wreghitt, T. J., Toxoplasmosis: A Comprehensive
Clinical Guide; Cambridge University Press: Cambridge, UK, 2001; p
395.
(5) Dubey, J. P.; Lago, E. G.; Gennari, S. M.; Su, C.; Jones, J. L.
Toxoplasmosis in humans and animals in Brazil: high prevalence, high
burden of disease, and epidemiology. Parasitology 2012, 139, 1375−
1424.
(6) McCabe, R. E., Antitoxoplasma chemotherapy. In Toxoplasmosis:
a Comprehensive Clinical Guide; Joynson, D. H. M., Wreghitt, T. G.,
Eds.; Cambridge University Press: Cambridge, UK, 2001; pp 319−
359.
(7) Sibley, L. D. How apicomplexan parasites move in and out of
cells. Curr. Opin. Biotechnol. 2010, 21, 592−598.
(8) Carruthers, V. B.; Giddings, O. K.; Sibley, L. D. Secretion of
micronemal proteins is associated with Toxoplasma invasion of host
cells. Cell Microbiol. 1999, 1, 225−236.
(9) Carruthers, V. B.; Moreno, S. N. J.; Sibley, L. D. Ethanol and
acetaldehyde elevate intracellular [Ca2+] calcium and stimulate
microneme discharge in Toxoplasma gondii. Biochem. J. 1999, 342,
379−386.
(26) Dunay, I. R.; Chan, W. C.; Haynes, R. K.; Sibley, L. D.
Artemisone and artemiside control acute and reactivated toxoplasmo-
sis in the murine model. Antimicrob. Agents Chemother. 2009, 53,
4450−4456.
(27) Hansch, C.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and central
nervous system agents: on the principle of minimal hydrophobicity in
drug design. J. Pharm. Sci. 1987, 76, 663−687.
(28) Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of
successful central nervous system drugs. NeuroRx 2005, 2, 541−553.
(29) Sugi, T.; Kato, K.; Kobayashi, K.; Kurokawa, H.; Takemae, H.;
Gong, H.; Recuenco, F. C.; Iwanaga, T.; Horimoto, T.; Akashi, H. 1-
NM-PP1 treatment of mice infected with Toxoplasma gondii. J. Vet.
Med. Sci. 2011, 73, 1377−1379.
(10) Lourido, S.; Shuman, J.; Zhang, C.; Shokat, K. M.; Hui, R.;
Sibley, L. D. Calcium-dependent protein kinase 1 is an essential
regulator of exocytosis in Toxoplasma. Nature 2010, 465, 359−362.
(11) Billker, O.; Lourido, S.; Sibley, L. D. Calcium-dependent
signaling and kinases in apicomplexan parasites. Cell Host Microbe
2009, 5, 612−622.
(12) Ojo, K. K.; Larson, E. T.; Keyloun, K. R.; Castaneda, L. J.;
DeRoucher, A. E.; KInampudi, K. K.; Kim, J. E.; Arakaki, T. L.;
Murphy, R. C.; Zhang, L.; Napuli, A. J.; Maly, D. J.; Verlinde, C. L. M.
J.; Buckner, F. S.; Parsons, M.; Hol, W. G. J.; Meritt, E. A.; Van
Voorhis, C. Toxoplasma gondii calcium-dependent protein kinase 1 is a
target for selective kinase inhibitors. Nature Struct. Mol. Biol. 2010, 17,
602−607.
3076
dx.doi.org/10.1021/jm4001314 | J. Med. Chem. 2013, 56, 3068−3077